Edgar Filing: ROE ROBERT L - Form 4

Form 4											
May 26, 201	А									PPROVAL	
-	UNITE	D STATES		ITIES Al hington, 1			IGE C	COMMISSION	OMB Number:	3235-0287	
Check thi if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	6. Filed p Section 1	EMENT O ursuant to S 7(a) of the 30(h)	Section 10 Public Ut	SECUR	burden hou response	Estimated average burden hours per					
(Print or Type F	Responses)										
1. Name and Address of Reporting Person <u>*</u> ROE ROBERT L			2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O CORCI THERAPEU COMMON		(Middle) VE	3. Date of (Month/D 05/26/20	-	insaction			Director X Officer (give below) Presid			
				endment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Table	e I - Non-Do	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)		any Code		Transactio	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common stock	05/26/2011			Code V M	Amount 13,400	(D) A	Price \$ 1.5	45,407	D		
Common stock	05/26/2011			S <u>(1)</u>	13,400	D	\$ 4.5	32,007	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: ROE ROBERT L - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date		7. Title and Amount of Underlying Securities8(Instr. 3 and 4)S(1)(1)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option	\$ 1.5	05/26/2011		М	13,400	(2)	04/16/2017	Common stock	13,400

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
ROE ROBERT L C/O CORCEPT THERAPEUTICS 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025			President and Secretary				
Signatures							
s/s Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated,							

attorney-in-fact

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale is made pursuant to terms of a 10b5-1 plan in effect at the time of sale of the shares.
- (2) Fully exerciseable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

05/26/2011

Date